Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 74 entries
View as:

A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT05804526 Org: User:
Start: 07/19/23 End: 12/31/25 Due: 12/31/26

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Phase: N/A Priority: Normal
NCT ID: NCT03556345 Org: User:
Start: 07/10/18 End: 08/31/20 Due: 08/31/21

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05745740 Org: User:
Start: 04/30/24 End: 12/31/25 Due: 12/31/26

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05297552 Org: User:
Start: 05/26/22 End: 02/28/25 Due: 02/28/26

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03052634 Org: User:
Start: 12/23/16 End: 04/07/23 Due: 04/07/24

A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04965519 Org: User:
Start: 12/21/21 End: 06/30/25 Due: 06/30/26

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

Phase: N/A Priority: Normal
NCT ID: NCT04082416 Org: User:
Start: 10/16/19 End: 06/30/22 Due: 06/30/23

Efficacy and Safety of RC28-E Versus Aflibercept

Phase: N/A Priority: Normal
NCT ID: NCT05727397 Org: User:
Start: 03/14/23 End: 12/29/25 Due: 12/29/26

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06105008 Org: User:
Start: 12/20/24 End: 04/10/26 Due: 04/10/27

A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours

Phase: N/A Priority: Normal
NCT ID: NCT05508334 Org: User:
Start: 01/30/23 End: 12/30/25 Due: 12/30/26

A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04617314 Org: User:
Start: 03/10/21 End: 12/31/25 Due: 12/31/26

A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05628857 Org: User:
Start: 11/11/22 End: 10/15/25 Due: 10/15/26

A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04329429 Org: User:
Start: 08/24/20 End: 06/30/24 Due: 06/30/25

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Phase: N/A Priority: Normal
NCT ID: NCT04714190 Org: User:
Start: 03/24/21 End: 06/30/25 Due: 06/30/26

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06227117 Org: User:
Start: 07/27/23 End: 12/31/26 Due: 12/31/27

A Study of RC18 Administered Subcutaneously to Subjects With Primary IgA(Immunoglobulin A) Nephropathy

Phase: N/A Priority: Normal
NCT ID: NCT04291781 Org: User:
Start: 04/13/20 End: 05/20/21 Due: 05/20/22

Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02881190 Org: User:
Start: 12/14/15 End: 11/08/19 Due: 11/08/20

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.

Phase: N/A Priority: Normal
NCT ID: NCT03016013 Org: User:
Start: 03/29/17 End: 12/29/22 Due: 12/29/23

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06155396 Org: User:
Start: 01/11/24 End: 12/31/27 Due: 12/31/28

A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT05673993 Org: User:
Start: 04/06/23 End: 05/06/25 Due: 05/06/26

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05980481 Org: User:
Start: 08/04/23 End: 07/10/25 Due: 07/10/26

A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders

Phase: N/A Priority: Normal
NCT ID: NCT03330418 Org: User:
Start: 01/29/18 End: 12/31/25 Due: 12/31/26

A Phase I Study of TACI-antibody Fusion Protein Injection (RC18) in Healthy Adult Chinese Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04235933 Org: User:
Start: 09/17/19 End: 12/20/19 Due: 12/20/20

A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02882087 Org: User:
Start: 10/31/15 End: 02/25/19 Due: 02/25/20

To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Phase: N/A Priority: Normal
NCT ID: NCT06378242 Org: User:
Start: 06/14/24 End: 12/31/29 Due: 12/31/30